Single-base LOH Can Be Used As Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes

Overview

Journal Breast J

Publisher Wiley

Date 2017 Jan 25

PMID 28117528

Citations 1

Authors

Bradley Downs

Fengxia Xiao

Yeong C Kim

Pei Xian Chen

Dali Huang

Elizabeth A Fleissner

Kenneth Cowan

San Ming Wang

Affiliations

Soon will be listed here.

Citing Articles

Roles of Loss of Chromosome 14q Allele in the Prognosis of Renal Cell Carcinoma with C-reactive Protein Abnormity.

Wang G, Zhang D, Zhuang H, Yin C, Liu J, Wang Z Chin Med J (Engl). 2017; 130(18):2176-2182.

PMID: 28875953 PMC: 5598329. DOI: 10.4103/0366-6999.213962.

References

Fernandez-Ramires R, Gomez G, Munoz-Repeto I, De Cecco L, Llort G, Cazorla A . Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors. Int J Cancer. 2010; 128(11):2635-44. DOI: 10.1002/ijc.25603. View

Melchor L, Honrado E, Garcia M, Alvarez S, Palacios J, Osorio A . Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene. 2007; 27(22):3165-75. DOI: 10.1038/sj.onc.1210975. View

Osorio A, de la Hoya M, Rodriguez-Lopez R, Martinez-Ramirez A, Cazorla A, Granizo J . Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer. 2002; 99(2):305-9. DOI: 10.1002/ijc.10337. View

Da Silva L, Lakhani S . Pathology of hereditary breast cancer. Mod Pathol. 2010; 23 Suppl 2:S46-51. DOI: 10.1038/modpathol.2010.37. View

Honrado E, Osorio A, Milne R, Paz M, Melchor L, Cascon A . Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol. 2007; 20(12):1298-306. DOI: 10.1038/modpathol.3800969. View

Didraga M, van Beers E, Joosse S, Brandwijk K, Oldenburg R, Wessels L . A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Res Treat. 2011; 130(2):425-36. DOI: 10.1007/s10549-011-1357-x. View

Topol E . Individualized medicine from prewomb to tomb. Cell. 2014; 157(1):241-53. PMC: 3995127. DOI: 10.1016/j.cell.2014.02.012. View

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A . Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003; 9(10 Pt 1):3606-14. View

Ghoussaini M, Pharoah P, Easton D . Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning?. Am J Pathol. 2013; 183(4):1038-1051. DOI: 10.1016/j.ajpath.2013.07.003. View

10.

Mangia A, Chiarappa P, Tommasi S, Chiriatti A, Petroni S, Schittulli F . Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers. Cancer Genet Cytogenet. 2008; 182(2):75-83. DOI: 10.1016/j.cancergencyto.2008.01.002. View

11.

Lakhani S, Reis-Filho J, Fulford L, Penault-Llorca F, van der Vijver M, Parry S . Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005; 11(14):5175-80. DOI: 10.1158/1078-0432.CCR-04-2424. View

12.

Tanic M, Andres E, Rodriguez-Pinilla S, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V . MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. Br J Cancer. 2013; 109(10):2724-34. PMC: 3833208. DOI: 10.1038/bjc.2013.612. View

13.

Huijsmans C, Poodt J, Damen J, van der Linden J, Savelkoul P, Pruijt J . Single nucleotide polymorphism (SNP)-based loss of heterozygosity (LOH) testing by real time PCR in patients suspect of myeloproliferative disease. PLoS One. 2012; 7(7):e38362. PMC: 3388082. DOI: 10.1371/journal.pone.0038362. View

14.

Oldenburg R, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen C, Hoogerbrugge N, van Leeuwen I . Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Clin Cancer Res. 2006; 12(6):1693-700. DOI: 10.1158/1078-0432.CCR-05-2230. View

15.

Arnold J, Choong D, Thompson E, Waddell N, Lindeman G, Visvader J . Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat. 2009; 119(2):491-6. DOI: 10.1007/s10549-008-0269-x. View

16.

Lakhani S, Gusterson B, Jacquemier J, Sloane J, Anderson T, van de Vijver M . The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000; 6(3):782-9. View